Hungary vs Serbia: Death rate from cancer
Hungary
311.62 deaths per 100,000 people
in 2021
Serbia
312.25 deaths per 100,000 people
in 2021
Hungary rank
6th
Serbia rank
5th
Death rate from cancer over time
- Hungary
- Serbia
How they compare
Serbia currently reports 312.25 deaths per 100,000 people against 311.62 deaths per 100,000 people in Hungary, a difference of 0.63 deaths per 100,000 people.
The two have swapped places 1 time across 22 shared years of data; in 2000 it was Hungary ahead.
Hungary ranks 6th and Serbia ranks 5th of 194 countries.
Across the 3 decades both report, Hungary averaged higher in 2 and Serbia in 1.
Head to head by decade
| Decade | Hungary | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 321.05 deaths per 100,000 people | 278.04 deaths per 100,000 people | 43.01 deaths per 100,000 people | Hungary |
| 2010s | 331.96 deaths per 100,000 people | 312.44 deaths per 100,000 people | 19.53 deaths per 100,000 people | Hungary |
| 2020s | 316.9 deaths per 100,000 people | 317.29 deaths per 100,000 people | 0.395 deaths per 100,000 people | Serbia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Hungary or Serbia?
- Serbia, at 312.25 deaths per 100,000 people against 311.62 deaths per 100,000 people in Hungary as of 2021.
- What is the difference in death rate from cancer between Hungary and Serbia?
- 0.63 deaths per 100,000 people, with Serbia ahead.
- How many years of comparable data are there for Hungary and Serbia?
- 22 years are reported by both, from 2000 to 2021.
- How do Hungary and Serbia rank globally for death rate from cancer?
- Hungary ranks 6th and Serbia ranks 5th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.